MS-553 is under clinical development by MingSight Pharmaceuticals and currently in Phase I for Diabetic Retinopathy. According to GlobalData, Phase I drugs for Diabetic Retinopathy have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MS-553’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MS-553 is under development for the treatment of diabetic retinopathy with macular edema, relapsed or refractory chronic lymphocytic lymphoma (CLL) or small lymphocytic lymphoma (SLL), b-cell non-Hodgkin lymphoma, mantle cell lymphoma. It is administered orally. MS-553 crosses the blood-retina barrier to achieve high concentrations in the retina. It is a new chemical entity.
MingSight Pharmaceuticals overview
MingSight Pharmaceuticals is a pharmaceutical company that specializes in developing selective inhibitor of protein kinase C beta, MS-553 in patients with diabetic macular edema and chronic lymphocytic leukemia. The company is headquartered in San Diego, California, the US.
For a complete picture of MS-553’s drug-specific PTSR and LoA scores, buy the report here.